Ayman Mahdy
Urology · Winter Park, FLNPI 1023248911
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Axonics, Inc. at 43.0% of the total. Reporting peaked in 2024 at $3,054 and has fallen 65.3% since, to $1,059 in 2025.
Across 163 payments — averaging $70.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- Medtronic$4K
- Boston Scientific$901
- Astellas Pharma US Inc$362
- Procept Biorobotics Corporation$298
- Teleflex LLC$273
- plus $1K from 10 others
Across 89 payments — averaging $1427.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axonics, Inc.$73K
- Sumitomo Pharma America, Inc.$53K
- Urovant Sciences Inc$625
What the payments were for
- Consulting fees$3,60031%
- Travel & lodging$2,17119%
- Food & beverage$5,54748%
- Education$2442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 34 | $4,970 |
| Medtronic(2 entities) | 57 | $3,730 |
| Boston Scientific | 19 | $901 |
| Astellas Pharma US Inc | 12 | $362 |
| Procept Biorobotics Corporation | 2 | $298 |
| Teleflex LLC | 2 | $273 |
| Sumitomo Pharma America, Inc. | 3 | $188 |
| C. R. Bard, Inc. & Subsidiaries | 11 | $179 |
| AbbVie | 14 | $175 |
| Coloplast | 1 | $152 |
| Dornier Medtech America, Inc | 1 | $124 |
| Johnson & Johnson | 1 | $113 |
| Rochester Medical Corporation | 3 | $36 |
| Blue Earth Diagnostics | 1 | $24 |
| Olympus America Inc. | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$4,611
- INTERSTIM$2,600
- AquaBeam Robotic System$298
- UroLift$273
- Axonics r-SNM System$156
- ALTIS$152
- GEMTESA$148
- Dornier MedTech$124
- Erleada$113
- LithoVue$102
How this compares
$11,562 in reported general payments places this provider in the 80th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 41 | $25,174 |
| GemtesaVibegron | 40 | $17,440 |
| Trospium Chloride | 59 | $4,694 |
| Estradiol | 39 | $2,187 |
| Gentamicin Sulfate | 39 | $2,118 |
| Tamsulosin Hcl | 124 | $1,289 |
| Solifenacin Succinate | 25 | $1,020 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $985 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $447 |
| Oxybutynin Chloride | 12 | $192 |
| Insulin SyringeSyringe And Needle,insulin,1ml | 24 | $162 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $116 |
| Finasteride | 17 | $103 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $83 |
| WaterWater For Irrigation,sterile | 16 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $362 | $25,17441 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $188 | $17,44040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 urology providers in Florida.
Other urology in Winter Park
- Justin EmtageWinter Park$62K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.